| Authors: |
Pant S; The University of Texas MD Anderson Cancer Center, Houston, TX, USA. spant@mdanderson.org., Wainberg ZA; University of California, Los Angeles, Los Angeles, CA, USA., Weekes CD; Massachusetts General Hospital, Boston, MA, USA., Furqan M; University of Iowa, Iowa City, IA, USA., Kasi PM; University of Iowa, Iowa City, IA, USA., Devoe CE; Northwell Health, Lake Success, NY, USA., Leal AD; University of Colorado School of Medicine, Aurora, CO, USA., Chung V; City of Hope, Duarte, CA, USA., Basturk O; Memorial Sloan Kettering Cancer Center, New York, NY, USA., VanWyk H; Elicio Therapeutics, Boston, MA, USA., Tavares AM; Elicio Therapeutics, Boston, MA, USA., Seenappa LM; Elicio Therapeutics, Boston, MA, USA., Perry JR; Elicio Therapeutics, Boston, MA, USA., Kheoh T; Elicio Therapeutics, Boston, MA, USA., McNeil LK; Elicio Therapeutics, Boston, MA, USA., Welkowsky E; Elicio Therapeutics, Boston, MA, USA., DeMuth PC; Elicio Therapeutics, Boston, MA, USA., Haqq CM; Elicio Therapeutics, Boston, MA, USA. chris.haqq@elicio.com., O'Reilly EM; Memorial Sloan Kettering Cancer Center, New York, NY, USA. oreillye@mskcc.org. |
